Results 1 to 10 of about 95 (52)

Eficácia e segurança de dois inaladores de pó seco usados para a aplicação de furoato de mometasona em pacientes com asma Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients

open access: yesJornal Brasileiro de Pneumologia, 2010
OBJETIVO: O furoato de mometasona (FM) é um novo corticosteroide inalatório sintético potente. Internacionalmente, o FM é fornecido em um inalador de pó seco que permite sua administração em múltiplas doses.
Carlos Alberto de Castro Pereira   +9 more
doaj   +1 more source

Multi-Gram Scale Synthesis and Characterization of Mometasone Furoate EP Impurity C. [PDF]

open access: yesMolecules, 2023
Ronchetti R   +6 more
europepmc   +1 more source

Effects of nigella sativa oil on allergic rhinitis: an experimental animal study. [PDF]

open access: yesBraz J Otorhinolaryngol, 2022
Gul R   +6 more
europepmc   +1 more source

Pharmacokinetic Evidence of Steady and Sustained Drug Release from Long-Acting Implantable Corticosteroid Matrices for Chronic Rhinosinusitis. [PDF]

open access: yesAm J Rhinol Allergy, 2022
Ow RA   +9 more
europepmc   +1 more source

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice. [PDF]

open access: yesPLoS One, 2021
Ziemba M   +8 more
europepmc   +1 more source

Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy. [PDF]

open access: yesJ Clin Pharmacol, 2020
Li X   +5 more
europepmc   +1 more source

Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. [PDF]

open access: yesProc Natl Acad Sci U S A, 2020
Liu X   +6 more
europepmc   +1 more source

Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys. [PDF]

open access: yesHum Mol Genet, 2020
Dang UJ   +6 more
europepmc   +1 more source

Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset. [PDF]

open access: yesInflamm Res, 2019
Damsker JM   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy